(Q44299607)

1 December 2017

Comparative pharmacokinetics and safety of lansoprazole oral capsules and orally disintegrating tablets in healthy subjects (English)

1 reference

1 December 2017

1 reference

Freston JW

1

1 reference

1 December 2017

Chiu YL

series ordinal

2

1 reference

1 December 2017

Mulford DJ

series ordinal

3

1 reference

1 December 2017

Ballard ED 2nd

series ordinal

4

1 reference

1 December 2017

language of work or name

English

0 references

publication date

1 February 2003

1 reference

Alimentary Pharmacology & Therapeutics

1 December 2017

1 reference

1 December 2017

17

1 reference

1 December 2017

3

1 reference

1 December 2017

361-367

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01455.X

1 December 2017

1 reference

Lansoprazole: an alternative method of administration of a capsule dosage formulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01455.X

A comparison of simplified lansoprazole suspension administered nasogastrically and pantoprazole administered intravenously: effects on 24-h intragastric pH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01455.X

Acid suppression in healthy subjects following lansoprazole or pantoprazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01455.X

Safety review in 10,008 users of lansoprazole in daily practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01455.X

Time to maximum effect of lansoprazole on gastric pH in normal male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01455.X

The comparative effects of lansoprazole, omeprazole, and ranitidine in suppressing gastric acid secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01455.X

Comparison of lansoprazole with omeprazole on 24-hour intragastric pH, acid secretion and serum gastrin in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01455.X

Lansoprazole versus omeprazole: influence on meal-stimulated gastric acid secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01455.X

The effects of oral doses of lansoprazole and omeprazole on gastric pH

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01455.X

Lansoprazole: administration of the contents of a capsule dosage formulation through a nasogastric tube

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01455.X

The pharmacodynamics of lansoprazole administered via gastrostomy as intact, non-encapsulated granules

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01455.X

The effects on intragastric acidity of per-gastrostomy administration of an alkaline suspension of omeprazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01455.X

10.1046/J.1365-2036.2003.01455.X

21 January 2018

Identifiers

DOI

1 reference

release_2eolcs5ejjap5ig2iuoeash2jq

1 December 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/2eolcs5ejjap5ig2iuoeash2jq

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference